凯赛生物
(688065)
| 流通市值：275.35亿 | | | 总市值：340.45亿 |
| 流通股本：5.83亿 | | | 总股本：7.21亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 775,769,935.75 | 2,957,911,554.76 | 2,215,083,356.3 | 1,444,292,958.19 |
| 营业收入 | 775,769,935.75 | 2,957,911,554.76 | 2,215,083,356.3 | 1,444,292,958.19 |
| 二、营业总成本 | 619,368,581.39 | 2,361,273,032.48 | 1,806,773,748.37 | 1,153,083,688.62 |
| 营业成本 | 514,850,598.38 | 2,033,666,835.61 | 1,501,857,748.48 | 993,336,401.18 |
| 税金及附加 | 9,240,459.11 | 35,788,319.56 | 27,474,697.65 | 18,507,963.2 |
| 销售费用 | 13,641,726.22 | 54,576,731.49 | 40,539,936.22 | 26,683,860.11 |
| 管理费用 | 43,022,810.13 | 167,912,474.07 | 131,707,996.74 | 85,512,207.47 |
| 研发费用 | 60,550,596.03 | 233,339,322.82 | 168,791,848.77 | 100,053,981.57 |
| 财务费用 | -21,937,608.48 | -164,010,651.07 | -63,598,479.49 | -71,010,724.91 |
| 其中:利息费用 | 7,000,087.54 | 27,433,126.5 | 22,180,831.53 | 15,276,793.52 |
| 其中:利息收入 | 31,187,657.19 | 160,754,505.67 | 117,548,630.92 | 75,142,826.9 |
| 加:投资收益 | -2,616,095.56 | -8,951,802.66 | -5,016,320.89 | -3,816,378.45 |
| 资产处置收益 | -288.89 | 403,263.87 | - | - |
| 资产减值损失(新) | -782,080.26 | -87,320,261.39 | -39,850,814.46 | -24,303,407.49 |
| 信用减值损失(新) | -4,394,492.06 | -3,340,568.52 | -6,242,589.28 | -4,584,000.02 |
| 其他收益 | 13,077,303.18 | 54,132,018.03 | 31,898,136.1 | 22,008,941.26 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 161,685,700.77 | 551,561,171.61 | 389,098,019.4 | 280,514,424.87 |
| 加:营业外收入 | 346,639.34 | 1,041,438.05 | 644,547.91 | 475,743.73 |
| 减:营业外支出 | 3,991,451.1 | 4,587,380.63 | 2,370,820.29 | 122,180.8 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 158,040,889.01 | 548,015,229.03 | 387,371,747.02 | 280,867,987.8 |
| 减:所得税费用 | 33,722,197.09 | 73,425,897.36 | 48,938,026.11 | 36,760,575.22 |
| 六、净利润 | 124,318,691.92 | 474,589,331.67 | 338,433,720.91 | 244,107,412.58 |
| 持续经营净利润 | 124,318,691.92 | 474,589,331.67 | 338,433,720.91 | 244,107,412.58 |
| 归属于母公司股东的净利润 | 136,950,113.57 | 488,961,919.11 | 345,177,417.97 | 247,445,607.49 |
| 少数股东损益 | -12,631,421.65 | -14,372,587.44 | -6,743,697.06 | -3,338,194.91 |
| (一)基本每股收益 | 0.23 | 0.84 | 0.59 | 0.42 |
| (二)稀释每股收益 | 0.23 | 0.84 | 0.59 | 0.42 |
| 八、其他综合收益 | 3,862,477.8 | -5,486,780.85 | 216,838.63 | -2,793,036.93 |
| 归属于母公司股东的其他综合收益 | 3,862,477.8 | -5,486,780.85 | 216,838.63 | -2,793,036.93 |
| 九、综合收益总额 | 128,181,169.72 | 469,102,550.82 | 338,650,559.54 | 241,314,375.65 |
| 归属于母公司股东的综合收益总额 | 140,812,591.37 | 483,475,138.26 | 345,394,256.6 | 244,652,570.56 |
| 归属于少数股东的综合收益总额 | -12,631,421.65 | -14,372,587.44 | -6,743,697.06 | -3,338,194.91 |
| 公告日期 | 2025-04-30 | 2025-04-22 | 2024-10-31 | 2024-08-16 |
| 审计意见(境内) | | 标准无保留意见 | | |